| NCT ID | NCT06450977 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Illinois at Urbana-Champaign |
| Condition | Multiple Sclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-06-07 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-06-07 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if increasing adherence to a Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet pattern improves thinking ability and memory compared to a healthy control diet in persons with Multiple Sclerosis (MS). The main question it aims to answer is: Does the MIND diet improve cognitive performance relative to a control diet in persons with MS? Participants will: Consume one meal that follows the MIND diet or a control meal every day for 3 months, complete online surveys and cognitive testing before and after, and keep a record of the food they eat during the study.
Eligibility Criteria
Inclusion Criteria: 1. Individuals aged 18-64 years old 2. Self-reported diagnosis of Multiple sclerosis (MS) 3. 20/20 or corrected vision 4. No other neurodegenerative disease diagnosis 5. Stable disease-modifying therapy (DMT) within 6 months 6. Not Pregnant or lactating 7. No food allergies or intolerances 8. Able to consume study meals 9. Not enrolled in another dietary, exercise, or medication study during the study 10. Access to a computer/laptop with internet Exclusion Criteria: 1. Individuals younger than 18 or older than 64 years old 2. No self-reported diagnosis of Multiple sclerosis (MS) 3. Not 20/20 or uncorrected vision 4. Other neurodegenerative disease diagnosis 5. Disease modifying therapy (DMT) less than 6 months 6. Pregnant or lactating 7. Food allergies or intolerances 8. Not able to consume study meals 9. Enrolled in another dietary, exercise, or medication study during the study 10. No access to a computer/laptop with internet
Contact & Investigator
Naiman Khan, PhD
PRINCIPAL INVESTIGATOR
University of Illinois Urbana-Champaign
Frequently Asked Questions
Who can join the NCT06450977 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 64 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06450977 currently recruiting?
Yes, NCT06450977 is actively recruiting participants. Contact the research team at nakhan2@illinois.edu for enrollment information.
Where is the NCT06450977 trial being conducted?
This trial is being conducted at Urbana, United States.
Who is sponsoring the NCT06450977 clinical trial?
NCT06450977 is sponsored by University of Illinois at Urbana-Champaign. The principal investigator is Naiman Khan, PhD at University of Illinois Urbana-Champaign. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.